Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical eff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) Jg. 390; H. 10106; S. 1962 - 1971
Hauptverfasser:	Giugliano, Robert P, Pedersen, Terje R, Park, Jeong-Gun, De Ferrari, Gaetano M, Gaciong, Zbigniew A, Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose, Schiele, François, Mach, François, Ott, Brian R, Kanevsky, Estella, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M, Keech, Anthony C, Sever, Peter S, Sabatine, Marc S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 28.10.2017 Elsevier Limited
Schlagworte:	Adult Aged Aged, 80 and over Angina Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - therapeutic use Arteriosclerosis Atherosclerosis Cardiovascular disease Cardiovascular diseases Cerebral infarction Cholesterol Cholesterol, LDL - blood Cholesterol, LDL - drug effects Clinical trials Diabetes Double-Blind Method Drug therapy Effectiveness Female Follow-Up Studies Health risk assessment Heart attacks Humans Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Inhibitor drugs Kexin Laboratories Lipids Low density lipoprotein Male Middle Aged Monoclonal antibodies Myocardial infarction Patient Safety Patients Proprotein Convertase 9 - antagonists & inhibitors Proprotein convertases Risk Assessment Risk factors Safety Secondary analysis Statins Stroke Subtilisin Treatment Outcome Triglycerides
ISSN:	0140-6736, 1474-547X, 1474-547X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!